Phosphodiesterase 5 inhibition in essential hypertension

Current Hypertension Reports

Volumn 10, Issue 1, 2008, Pages 52-57

  Ghiadoni, Lorenzo ^b   Versari, Daniele ^b   Taddei, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; METOPROLOL; NIFEDIPINE; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; TAMSULOSIN; THIAZIDE DIURETIC AGENT; VARDENAFIL;

CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; ERECTILE DYSFUNCTION; ESSENTIAL HYPERTENSION; FLUSHING; HUMAN; LONG TERM EXPOSURE; MONOTHERAPY; MORNING DOSAGE; ORTHOSTATIC HYPERTENSION; ORTHOSTATIC HYPOTENSION; PROGNOSIS; PROSTATE HYPERTROPHY; PULMONARY HYPERTENSION; PULSE WAVE; REVIEW; RHINITIS; SIDE EFFECT; SINGLE DRUG DOSE; SLOW DRUG RELEASE; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VASCULAR RESISTANCE; VASODILATATION; VISUAL DISORDER;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARBOLINES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ENDOTHELIUM; HUMANS; HYPERTENSION; IMIDAZOLES; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SULFONES; TRIAZINES;

EID: 39149103089     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-008-0011-4     Document Type: Review

References (50)

1. Beavo JA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995, 75:725-748.
2. Hofmann F, Ammendola A, Schlossmann J: Rising behind NO: cGMP-dependent protein kinases. J Cell Sci 2000, 113:1671-1676.
3. Rybalkin SD, Yan C, Bornfeldt KE, et al.: Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 2003, 93:280-291.
4. Carson CC, Lue TF: Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int 2005, 96:257-280.
5. Ghofrani HA, Osterloh IH, Grimminger F: Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006, 5:689-702.
6. Kloner RA: Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004, 110:3149-3155.
7. Goldstein I, Lue TF, Padma-Nathan H, et al.: Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998, 338:1397-1404.
8. Hellstrom WJ, Gittelman M, Karlin G, et al.: Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002, 23:763-771.
9. Brock GB, McMahon CG, Chen KK, et al.: Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002, 168:1332-1336.
10. Galie N, Ghofrani HA, Torbicki A, et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148-157.
11. Feldman HA, Johannes CB, Derby CA, et al.: Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med 2000, 30:328-338.
12. Taddei S, Ghiadoni L: Phosphodiesterase 5 inhibition to treat essential hypertension: is this the beginning of the story? Hypertension 2006, 48:546-548.
13. Mancia G, De Backer G, Dominiczak A, et al.: 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007, 28:1462-1536.
14. Williams B, Lacy PS, Thom SM, et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006, 113:1213-1225.
15. Laurent S, Cockcroft J, Van Bortel L, et al.: Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006, 27:2588-2605.
16. Boutouyrie P, Tropeano AI, Asmar R, et al.: Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002, 39:10-15.
17. Taddei S, Virdis A, Ghiadoni L, et al.: Effects of anti-hypertensive drugs on endothelial dysfunction: clinical implications. Drugs 2002, 62:265-284.
18. Modena MG, Bonetti L, Coppi F, et al.: Prognostic role of reversible endothelial dysfunction in hypertensive post-menopausal women. J Am Coll Cardiol 2002, 40:505-510.
19. Jackson G, Benjamin N, Jackson N, et al.: Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999, 83:13C-20C.
20. Zusman RM, Morales A, Glasser DB, et al.: Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999, 83:35C-44C.
21. Pomara G, Morelli G, Pomara S, et al.: Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil. J Androl 2004, 25:625-629.
22. Kloner RA, Mitchell M, Emmick JT: Cardiovascular effects of tadalafil. Am J Cardiol 2003, 92:37M-46M.
23. Herrmann HC, Chang G, Klugherz BD, et al.: Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000, 342:1622-1626.
24. Mahmud A, Hennessy M, Feely J: Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. J Hum Hypertens 2001, 15:707-713.
25. Vardi Y, Klein L, Nassar S, et al.: Effects of sildenafil citrate (Viagra) on blood pressure in normotensive and hypertensive men. Urology 2002, 59:747-752.
26. Webb DJ, Freestone S, Allen MJ, et al.: Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol 1999, 83:21C-28C.
27. Oliver JJ, Melville VP, Webb DJ: Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension 2006, 48:622-627.
28. Giles TD: Circadian rhythm of blood pressure and the relation to cardiovascular events. J Hypertens Suppl 2006, 24:S11-S16.
29. Zusman RM, Prisant LM, Brown MJ: Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group. J Hypertens 2000, 18:1865-1869.
30. Kloner RA, Brown M, Prisant LM, et al.: Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. Am J Hypertens 2001, 14:70-73.
31. Pickering TG, Shepherd AM, Puddey I, et al.: Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. Am J Hypertens 2004, 17:1135-1142.
32. Kloner RA, Mitchell M, Emmick JT: Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 2003, 92:47M-57M.
33. Kloner RA: Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions Am J Cardiol 2005, 96:42M-46M.
34. Vlachopoulos C, Hirata K, O'Rourke MF: Effect of sildenafil on arterial stiffness and wave reflection. Vasc Med 2003, 8:243-248.
35. Hirata K, Adji A, Vlachopoulos C, et al.: Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol 2005, 96:1436-1440.
36. Schofield RS, Edwards DG, Schuler BT, et al.: Vascular effects of sildenafil in hypertensive cardiac transplant recipients. Am J Hypertens 2003, 16:874-877.
37. Wilkinson IB, MacCallum H, Hupperetz PC, et al.: Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and noradrenaline in man. J Physiol 2001, 530:541-550
38. Stokes GS, Barin ES, Gilfillan KL: Effects of isosorbide mononitrate and AII inhibition on pulse wave reflection in hypertension. Hypertension 2003, 41:297-301.
39. O'Rourke MF, Nichols WW: Changes in wave reflection with advancing age in normal subjects. Hypertension 2004, 44:e10-e11.
40. McDonald LJ, Murad F: Nitric oxide and cyclic GMP signaling. Proc Soc Exp Biol Med 1996, 211:1-6.
41. Dishy V, Sofowora G, Harris PA, et al.: The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. Clin Pharmacol Ther 2001, 70:270-279.
42. Halcox JP, Nour KR, Zalos G, et al.: The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002, 40:1232-1240.
43. Hryniewicz K, Dimayuga C, Hudaihed A, et al.: Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure. Clin Sci 2005, 108:331-338.
44. Kimura M, Higashi Y, Hara K, et al.: PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers. Hypertension 2003, 41:1106-1110.
45. Vlachopoulos C, Tsekoura D, Alexopoulos N, et al.: Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction. Am J Hypertens 2004, 17:1040-1044.
46. Robinson SD, Ludlam CA, Boon NA, et al.: Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease. Heart 2006, 92:170-176.
47. Dishy V, Harris PA, Pierce R, et al.: Sildenafil does not improve nitric oxide-mediated endothelium-dependent vascular responses in smokers. Br J Clin Pharmacol 2004, 57:209-212.
48. Taddei S, Ghiadoni L, Virdis A, et al.: Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients. Circulation 1999, 100:1400-1405.
49. Corretti MC, Anderson TJ, Benjamin EJ, et al.: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39:257-265.
50. Deanfield J, Donald A, Ferri C, et al.: Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005, 23:7-17.